Vasculitis associated with the use of an intrauterine device: A case report

Ghita,Aurelian Mihai; Alexandrescu,Cristina; Istrate,Sanziana; Evsei,Anca; Ghita,Ana Cristina

doi:10.3892/etm.2021.10712

Vasculitis associated with the use of an intrauterine device: A case report

Authors:
- Aurelian Mihai Ghita
- Cristina Alexandrescu
- Sanziana Istrate
- Anca Evsei
- Ana Cristina Ghita
View Affiliations

Affiliations: Department of Physiology II, Faculty of Medicine, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Ophthalmology, Faculty of Dentistry, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Pathology, ‘Sf. Maria’ Clinical Hospital, 011172 Bucharest, Romania, Department of Ophthalmology, Ocularcare Eye Clinic, 011204 Bucharest, Romania
Published online on: September 8, 2021 https://doi.org/10.3892/etm.2021.10712
Article Number: 1277
Copyright: © Ghita et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinal vasculitis is a complication associated with a local condition or it can be a retinal expression of a systemic inflammatory disorder, which initially may go unnoticed. Drug‑associated vasculitis is frequently difficult to identify, because many patients follow treatments with more than one drug and the route of administration varies. A 35‑year‑old female patient presented with sudden hearing loss, headache and blurred vision that had started two weeks earlier and had become progressively worse. Ophthalmological examination revealed anterior uveitis, bilateral optic disc swelling and retinal vasculitis. The orbito‑cerebral MRI, the CT scan and the serological tests were within normal limits. Unable to identify the cause of the retinal vasculitis, the patient's medical history was reviewed. The patient had recently had a gynecological procedure, where a 13.5 mg levonorgestrel intrauterine contraceptive device was implanted. After the device was removed and methylprednisolone treatment started, the patient presented a visible remission of the symptoms and signs. To the best of our knowledge, there is no case of retinal disease and optic disc edema associated with auditory problems caused by an intrauterine device. A proper examination, correlated with a very thorough medical history, could identify rare diseases and associations, in order to provide adequate medical care.

View Figures

View References

1	Guillevin L and Dorner T: Vasculitis: Mechanisms involved and clinical manifestations. Arthritis Res Ther. 9 (Suppl 2)(S9)2007.PubMed/NCBI View Article : Google Scholar
2	Langford CA: Vasculitis. J Allergy Clin Immunol. 125 (Suppl 2):S216–S225. 2010.PubMed/NCBI View Article : Google Scholar
3	Trese MGJ, Yonekawa Y, Thomas BJ and Randhawa S: Vasculitic central retinal vein occlusion: The presenting sign of seronegative rheumatoid arthritis. Am J Ophthalmol Case Rep. 2:26–29. 2016.PubMed/NCBI View Article : Google Scholar
4	Rosenbaum JT, Sibley CH and Lin P: Retinal vasculitis. Curr Opin Rheumatol. 28:228–235. 2016.PubMed/NCBI View Article : Google Scholar
5	Jennette JC: Overview of the 2012 revised International chapel hill consensus conference nomenclature of vasculitides. Clin Exp Nephrol. 17:603–606. 2013.PubMed/NCBI View Article : Google Scholar
6	Apinyawasisuk S, Rothova A, Kunavisarut P and Pathanapitoon K: Clinical features and etiology of retinal vasculitis in Northern Thailand. Indian J Ophthalmol. 61:739–742. 2013.PubMed/NCBI View Article : Google Scholar
7	Fukunaga H, Kaburaki T, Shirahama S, Tanaka R, Murata H, Sato T, Takeuchi M, Tozawa H, Urade Y, Katsura M, et al: Analysis of inflammatory mediators in the vitreous humor of eyes with pan-uveitis according to aetiological classification. Sci Rep. 10(2783)2020.PubMed/NCBI View Article : Google Scholar
8	Kaburaki T, Fukunaga H, Tanaka R, Nakahara H, Kawashima H, Shirahama S, Izawa H, Komae K, Takamoto M, Soga H and Aihara M: Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. Jpn J Ophthalmol. 64:150–159. 2020.PubMed/NCBI View Article : Google Scholar
9	Agarwal A, Karkhur S, Aggarwal K, Invernizzi A, Singh R, Dogra MR, Gupta V, Gupta A, Do DV and Nguyen QD: Epidemiology and clinical features of inflammatory retinal vascular occlusions: Pooled data from two tertiary-referral institutions. Clin Exp Ophthalmol. 46:62–74. 2018.PubMed/NCBI View Article : Google Scholar
10	Grau RG: Drug-induced vasculitis: New insights and a changing lineup of suspects. Curr Rheumatol Rep. 17(71)2015.PubMed/NCBI View Article : Google Scholar
11	Iwahashi C, Ono H, Haruta M, Minami T, Mashimo H, Shimojo H and Ohguro N: New onset or exacerbation of uveitis with infliximab: Paradoxical effects? BMJ Open Ophthalmol. 4(e000250)2019.PubMed/NCBI View Article : Google Scholar
12	Agarwal A, Pilania RK, Anjani G, Choudhary H, Gupta A and Gupta V: Retinal vasculitis with coats-like response in a young girl with Parry-Romberg syndrome. J Clin Rheumatol: May 21, 2019 (Epub ahead of print).
13	Mosovich B, Biton A and Avinoach I: Vasculitis with cutaneous necrosis induced by oral contraceptive. Harefuah. 120:451–453. 1991.PubMed/NCBI(In Hebrew).
14	Trusau A and Brit ML: Propylthiouracil-induced ANCA-negative cutaneous small vessel vasculitis. J Community Hosp Intern Med Perspect. 8:35–37. 2018.PubMed/NCBI View Article : Google Scholar
15	Wiik A: Drug-induced vasculitis. Curr Opin Rheumatol. 20:35–39. 2008.PubMed/NCBI View Article : Google Scholar
16	Kailasam C and Cahill D: Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. Patient Prefer Adherence. 2:293–302. 2008.PubMed/NCBI View Article : Google Scholar
17	Andersson K, Odlind V and Rybo G: Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. Contraception. 49:56–72. 1994.PubMed/NCBI View Article : Google Scholar
18	Sturridge F and Guillebaud J: A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf. 15:430–440. 1996.PubMed/NCBI View Article : Google Scholar
19	Vrettakos C and Bajaj T: Levonorgestrel. In: StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2021.
20	Abu El-Asrar AM, Herbort CP and Tabbara KF: Differential diagnosis of retinal vasculitis. Middle East Afr J Ophthalmol. 16:202–218. 2009.PubMed/NCBI View Article : Google Scholar
21	Wildemeersch D, Andrade A, Goldstuck ND, Hasskamp T and Jackers G: Intrauterine levonorgestrel delivery with frameless fibrous delivery system: Review of clinical experience. Int J Womens Health. 9:49–58. 2017.PubMed/NCBI View Article : Google Scholar
22	Fekete GL and Fekete L: Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature. Exp Ther Med. 17:1128–1131. 2019.PubMed/NCBI View Article : Google Scholar
23	Mansour D: The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contraception. 85:224–234. 2012.PubMed/NCBI View Article : Google Scholar
24	Radic M, Martinović Kaliterna D and Radic J: Drug-induced vasculitis: A clinical and pathological review. Neth J Med. 70:12–17. 2012.PubMed/NCBI
25	Papaliodis GN: Ophthalmologic manifestations of systemic vasculitis. Curr Opin Ophthalmol. 28:613–616. 2017.PubMed/NCBI View Article : Google Scholar
26	Tugal-Tutkun I: Systemic vasculitis and the eye. Curr Opin Rheumatol. 29:24–32. 2017.PubMed/NCBI View Article : Google Scholar
27	Iliescu DA, Timaru CM, Batras M, De Simone A and Stefan C: Cogan's syndrome. Rom J Ophthalmol. 59:6–13. 2015.PubMed/NCBI
28	Vollertsen RS: Vasculitis and Cogan's syndrome. Rheum Dis Clin North Am. 16:433–439. 1990.PubMed/NCBI
29	Behera SK, Das S, Xavier AS, Velupula S and Sandhiya S: Comparison of different methods for causality assessment of adverse drug reactions. Int J Clin Pharm. 40:903–910. 2018.PubMed/NCBI View Article : Google Scholar
30	Murayama H, Sakuma M, Takahashi Y and Morimoto T: Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan adverse drug events study. Pharmacol Res Perspect. 6(e00373)2018.PubMed/NCBI View Article : Google Scholar
31	Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 30:239–245. 1981.PubMed/NCBI View Article : Google Scholar